LoDoCo2 Trial
New England Journal of Medicine (2020)
0.5mg daily reduced MACE by 31% (HR 0.69) in 5,522 stable CAD patients on background statin/antiplatelet.
How it works
Marek's Guided Optimization® Program combines advanced lab testing, a dedicated health coach and medical provider, and a personalized treatment plan, all built around your data.
Resources
The process
Start your assessment
Complete your 45-min intake assessment
Get your labs drawn
4,000 partnered lab locations nationwide
Review with your coach
Screen-by-screen lab review
Receive your protocol
Treatment delivered to your door
Why Marek
The only program pairing you with a dedicated health coach and medical provider, built on precision diagnostics, with no subscription required.
Resources
Meet our co-founder
Derek
Co-Founder · MPMD Podcast
"Over time, I found it incredibly difficult to get medical oversight for myself and my family that reflected the latest research, and that was preventative. That's why I started Marek Health."

What we test
Every client's lab panel is hand-selected from 1,000+ available biomarkers, built around their specific goals.
Panel categories
Resources
Treatments
700+ medical provider-prescribed therapies built from your labs. Browse by category or explore the full formulary.
Colchicine
Oral tablet (0.6mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
Ancient alkaloid with potent anti-inflammatory properties. LoDoCo2 and COLCOT trials demonstrated 0.5mg daily significantly reduces MACE in stable CAD and post-ACS, targeting residual inflammatory risk not addressed by lipid lowering.
31% MACE reduction in stable CAD (LoDoCo2)
23% MACE reduction post-ACS (COLCOT)
Targets NLRP3/IL-1beta, additive to statins
Low cost (generic)
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Inhibits tubulin polymerization, disrupting NLRP3 inflammasome activation, neutrophil chemotaxis, and IL-1beta/IL-18 secretion. Potent inhibition of innate inflammatory response underlying plaque destabilization.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Sex hormones
Adrenals & neurosteroids
Growth hormone / IGF-1
Thyroid hormones
Cardiovascular health
Insulin sensitivity
Liver & pancreas
Kidney function
Comprehensive Metabolic Panel (CMP)
Prostate health
Vitamins & minerals
Iron status
Complete Blood Count (CBC)
Clinical evidence
New England Journal of Medicine (2020)
0.5mg daily reduced MACE by 31% (HR 0.69) in 5,522 stable CAD patients on background statin/antiplatelet.
New England Journal of Medicine (2019)
0.5mg daily reduced MACE by 23% when initiated within 30 days of MI.
Safety profile
FAQ
Ancient alkaloid with potent anti-inflammatory properties. LoDoCo2 and COLCOT trials demonstrated 0.5mg daily significantly reduces MACE in stable CAD and post-ACS, targeting residual inflammatory risk not addressed by lipid lowering.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.